[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cachexia-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cachexia-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,68,97,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100605876","phase-2-phase-2-cachexia-clinical-trial-to-evaluate-the-efficacy-and-safety-of-asca101-100605876",false,"NCT07168226","Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor","Inclusion Criteria:\n\nTo be eligible for enrollment, subjects must meet all of the following criteria.\n\n1. Aged 19 years or older with a histologically or cytologically confirmed diagnosis of a solid tumor (primary tumor types: colorectal cancer, ovarian cancer, and lung cancer \\[lung cancer applicable to Study 1 only\\]).\n2. Must be either surgically sterilized or postmenopausal\\*. (For female subjects only)\n\n   \\*Postmenopause is defined as the permanent cessation of ovarian function, evidenced by the absence of menstruation for 12 consecutive months not attributable to other medical causes.\n3. Must meet at least one of the following criteria consistent with cachexia diagnosis\\*:\n\n   ① Unintentional weight loss of \\>5% over the past 6 months.\n\n   ② BMI \\\u003C20 kg\u002Fm² with unintentional weight loss of \\>2% over the past 6 months.\n\n   ③ Diagnosis of sarcopenia (skeletal muscle index: \\\u003C7.26 kg\u002Fm² for men, \\\u003C5.45 kg\u002Fm² for women) with unintentional weight loss of \\>2% over the past 6 months.\n\n   \\*For subjects requiring confirmation of sarcopenia for cachexia diagnosis, skeletal muscle mass must be assessed using Dual-Energy X-ray Absorptiometry (DEXA).\n4. Clinical laboratory results measured within 14 days prior to randomization must meet the following criteria :\n\n   * Absolute Neutrophil Count (ANC) ≥ 1,000\u002Fmm³\n\n     * Platelet count ≥ 75,000\u002Fmm³\n\n       * Hemoglobin ≥ 8.0 g\u002FdL ④ Serum creatinine ≤ 2 × upper limit of normal (ULN) ⑤ Total bilirubin ≤ 3 × ULN ⑥ AST and ALT ≤ 3 × ULN (≤ 5 × ULN if liver metastasis is present)\n\n         * INR and aPTT ≤ 1.5 × ULN\n5. Able to consume food orally.\n6. Able to complete questionnaires.\n7. Life expectancy of at least 16 weeks, as assessed by the investigator.\n8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3.\n9. Male subjects who have not undergone vasectomy must agree to use highly effective contraception from at least 4 weeks prior to study drug administration, throughout the study period, and for 6 months following the last dose.\n\n   Highly effective contraception includes: partner's hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, or total sexual abstinence.\n10. Able and willing to voluntarily provide written informed consent to participate in this clinical trial.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will be excluded from enrollment.\n\n1. Patients who meet any of the following criteria:\n\n   ① Are scheduled to undergo surgery requiring general anesthesia for the treatment of cancer.\n\n   ② Are scheduled to switch to, or initiate an additional anticancer treatment regimen other than the chemotherapy (including chemoimmunotherapy) or radiotherapy currently being administered.\n\n   ③ Are receiving, or are scheduled to receive, hormonal therapy or immunotherapy.\n2. History of hypersensitivity to any component of the investigational product or to drugs of the same class.\n3. Currently taking medications for the purpose of appetite stimulation or weight gain.\n4. History of surgery within 3 months prior to screening. (Note: Subjects undergoing postoperative chemotherapy are eligible regardless of the time of surgery.)\n5. Subjects requiring dietary restrictions.\n6. Subjects requiring enteral or parenteral nutrition.\n7. Weight loss due to causes other than malignancy, including:\n\n   * Major endocrine\u002Fmetabolic disorders (e.g., hyperthyroidism, uncontrolled diabetes mellitus)\n   * Conditions affecting appetite or calorie intake (e.g., mechanical bowel obstruction, cholestasis, uncontrolled nausea\u002Fvomiting, malabsorption syndromes, severe diarrhea)\n8. Conditions that may lead to weight gain, including major endocrine\u002Fmetabolic diseases (e.g., hypothyroidism, Cushing's syndrome).\n9. History of any of the following cardiovascular conditions within the past 5 years:\n\n   * Congestive heart failure (CHF) classified as NYHA Class II or higher, or LVEF\n\n     * 50%\n   * Uncontrolled hypertension\n   * History of hypertensive crisis or hypertensive encephalopathy\n   * Pulmonary hypertension\n   * Myocardial infarction\n   * Clinically significant vascular disease within 6 months prior to the first dose (e.g., aneurysm requiring surgery, recent peripheral arterial thrombosis)\n   * Uncontrolled arrhythmias\n10. Persistent clinically significant toxicity (Grade ≥2 per NCI-CTCAE v5.0) due to previous cancer treatment.\n11. Subjects with severe infections or severe traumatic systemic conditions.\n12. Symptomatic or uncontrolled central nervous system (CNS) metastases. (Note: Subjects with asymptomatic CNS metastases who have discontinued systemic corticosteroids at least 4 weeks prior to randomization and have been radiologically and neurologically stable for ≥4 weeks are eligible.)\n13. Patients with one or more contraindications to ascorbic acid injection and\u002For calcium injection, including:\n\n    * Hyperoxaluria, thalassemia\n    * Gout, cystinuria\n    * Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n    * Calcium oxalate nephrolithiasis\n    * Receiving cardiac glycosides\n    * Hypercalcemia (Ca ≥10.5 mg\u002FdL)\n    * History of kidney stones with hypercalciuria\n    * Sarcoidosis\n    * Nephrolithiasis\n    * Hypoproteinemia (Total protein ≤6.0 g\u002FdL)\n    * Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin)\n14. Patients with severe neurological or psychiatric disorders that, in the investigator's judgment, are sufficient to affect the clinical trial outcomes (e.g., depression, dementia, delirium).\n15. Patients who are breastfeeding or who, or whose partners, are planning to become pregnant during the clinical trial period.\n16. Individuals who have participated in another clinical trial within 30 days prior to screening.\n17. Patients with a history of bleeding-related or gastrointestinal diseases, as described below:\n\n    * Evidence of active bleeding, bleeding diathesis, coagulopathy, or tumors involving major blood vessels.\n    * Clinically significant peptic ulcers, gastrointestinal bleeding, gastrointestinal or non-gastrointestinal fistulas, perforations, intra-abdominal abscesses, signs or symptoms of gastrointestinal obstruction, requirement of parenteral hydration or nutrition, or a history of inflammatory bowel disease (IBD).\n    * Evidence of free air in the abdomen not explained by paracentesis or recent surgical procedures.\n18. Patients who have received biguanides (e.g., metformin) within 2 weeks prior to screening or are expected to require them during the clinical trial.\n19. Patients requiring continuous systemic corticosteroid therapy (exceptions allowed as below):\n\n    * Use of local corticosteroids such as intra-articular, intranasal, ophthalmic, or inhaled corticosteroids is permitted.\n    * Temporary systemic corticosteroid use for treatment or prevention of contrast agent allergy or adverse events is allowed.\n20. Patients with HIV or other severe diseases deemed by the investigator to make study participation inappropriate.\n21. Patients who underwent drainage of ascites and\u002For pleural effusion within 14 days prior to screening.\n22. Patients with hemoptysis (defined as ≥1\u002F2 teaspoon of bright red blood per episode) within 14 days prior to screening.\n23. Patients who underwent core biopsy or other minor surgical procedures (excluding vascular access device placement) within 3 days prior to the first administration of the investigational product.\n24. Patients with significant, unhealed wounds, active ulcers, or untreated fractures.\n25. Patients with a history of cerebrovascular accident (stroke), transient ischemic attack, or subarachnoid hemorrhage within 6 months prior to screening.\n26. Patients with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n27. Any other condition deemed by the investigator to make the patient unsuitable for participation in the clinical trial.\n\n    \\[Exclusion Criteria Applicable Only to Study 1\\]\n28. Patients with a history of hypersensitivity to megestrol acetate or any of its components.\n29. Patients who have been receiving continuous antithrombotic therapy (antiplatelet agents, oral anticoagulants, or a combination thereof) within 4 weeks prior to screening, or who are anticipated to require antithrombotic therapy during the study period.\n30. Patients with diabetes mellitus.","ALL","19 Years",{"count":19,"type":20},135,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients. The main questions it aims to answer are:\n\nCan the efficacy of ASCA101 in improving cachexia be evaluated based on changes in body weight measured by InBody after 12 weeks (3 cycles) of weekly administration, compared to baseline, for each dose group?\n\nDo participants experience adverse events during administration of ASCA101 and\u002For within 4 weeks after the end of administration?\n\nThis clinical trial comprises two parts. \\[Study 1. Active-Controlled, Open-Label Study\\] Participants who provide written informed consent will undergo screening procedures. Those who meet all inclusion criteria and none of the exclusion criteria will be eligible for enrollment and will be randomized to receive either ASCA101 (at one of two dose levels: 24.32 or 32.43 mg\u002Fkg) or an active control. Participants will receive the investigational product over 3 cycles (12 weeks). Each cycle consists of 28 days. Subjects in the ASCA101 group will receive the investigational drug twice weekly for a total of 8 doses per cycle. Participants in the active control group (megace F suspension) will receive the drug orally once daily.\n\n\\[Study 2. Placebo-Controlled, Double-Blind Study\\] Participants who provide written informed consent will undergo screening procedures. Those who meet all inclusion criteria and none of the exclusion criteria will be eligible for enrollment and will be randomized to receive either ASCA101 (at one of two dose levels: 24.32 or 32.43 mg\u002Fkg) or placebo. Participants will receive the investigational product over 3 cycles (12 weeks). Each cycle consists of 28 days. Subjects in the ASCA101 group will receive the investigational drug twice weekly for a total of 8 doses per cycle. Participants in the placebo group will receive placebo in the same manner as the ASCA101 group.",[26],"Cachexia; Cancer","RECRUITING","2026-06-15",{"date":30,"type":31},"2026-06-17","ACTUAL",{"date":33,"type":31},"2026-05-08",{"date":35,"type":20},"2028-06-30",{"name":37,"class":38},"MetaFines","INDUSTRY",6,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100632890","phase-1-a-phase-i-clinical-study-to-evaluate-the-efficacy-and-safety-of-gb18-injection-in-patients-with-tumor-cachexia-100632890","NCT07519564","A Phase I Clinical Study to Evaluate the Efficacy and Safety of GB18 Injection in Patients With Tumor Cachexia","A Phase I Clinical Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of GB18 Injection in Patients With Tumor Cachexia","Key Inclusion Criteria:\n\n* Voluntarily serve as a participant and sign the informed consent form;\n* Age ≥ 18 years;\n* Histologically or cytologically confirmed, non-resectable, locally advanced, recurrent, or metastatic solid tumors with failed standard treatment or have no standard treatment options. This includes, but is not limited to, colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, biliary tract cancer, non-small cell lung cancer, prostate cancer, breast cancer, or ovarian cancer.\n* Diagnosed with cancer cachexia: BMI \\\u003C 18.5 kg\u002Fm², and no unintentional weight loss \\> 2% within 6 months before screening, or no unintentional weight loss \\> 5% within 6 months before screening regardless of BMI.\n* A serum GDF15 concentration ≥ 1.5 ng\u002FmL.\n* Laboratory Test Requirements:\n\n  1. Absolute neutrophil count ≥ 1.0 × 10⁹\u002FL, platelet count ≥ 75 × 10⁹\u002FL, hemoglobin ≥ 80 g\u002FL.\n  2. Serum creatinine ≤ 1.5 × ULN (Upper Limit of Normal).\n  3. Total bilirubin ≤ 1.5 × ULN, AST and ALT ≤ 3 × ULN (or ≤ 5 × ULN for patients with liver metastasis).\n  4. Activated partial thromboplastin time ≤ 1.5 × ULN, International Normalized Ratio ≤ 1.5.\n  5. Left Ventricular Ejection Fraction \\> 50% as assessed by echocardiogram.\n* Eastern Cooperative Oncology Group (ECOG) performance status score: 0-2 points\n* Expected survival period ≥ 4 months.\n\nKey Exclusion Criteria:\n\n* Known active\u002Fsymptomatic central nervous system metastases and\u002For carcinomatous meningitis.\n* Plan to receive radiotherapy as a component of the primary antitumor treatment regimen.\n* BMI \\> 26 kg\u002Fm².\n* Presence of reversible causes for reduced food intake, including but not limited to NCI CTCAE grade 3 or 4 oral mucositis; NCI CTCAE grade 3 or 4 nausea, vomiting, diarrhea, or constipation; mechanical obstruction preventing oral intake.\n* Comorbid conditions unrelated to tumor cachexia that cause difficulty in eating or malabsorption.\n* Cachexia due to other investigator-determined or clearly defined causes. History within the past 6 months of any of the following: myocardial infarction, congenital long QT syndrome, second- or third-degree atrioventricular block, arrhythmias (including sustained ventricular tachycardia or ventricular fibrillation), unstable angina, acute coronary syndrome, symptomatic congestive heart failure (NYHA class III or IV) of coronary or peripheral origin, stroke, transient ischemic attack, or symptomatic pulmonary embolism or other clinically significant thromboembolic disease.\n* Hypertension with unsatisfactory control despite antihypertensive therapy (defined as systolic blood pressure \\> 150 mmHg or diastolic blood pressure \\> 90 mmHg).\n* Patients receiving tube feeding or parenteral nutrition (total or partial) within 28 days before the first administration of the investigational drug.\n* Initiation of new systemic glucocorticoid therapy from 28 days before the first dose of the investigational drug to the end of the study.\n* Major surgery not yet recovered from within 28 days before the first dose of the investigational drug (central venous access placement and tumor biopsy are not considered major surgery), or anticipated major surgery during the study period.\n* Prior participation in clinical trials targeting the GDF-15\u002FGFRAL signaling pathways, or receipt of other investigational agents within 28 days or five half-lives (whichever is shorter) before the first dose of the investigational drug.\n* Severe infection requiring intravenous antibiotics, antivirals, or antifungal agents within 14 days before the first dose of the investigational drug.","18 Years",{"count":49,"type":20},18,[51],"PHASE1","KXZY-GB18-101(1B) is an extension of KXZY-GB18-101, a first-in-human, dose-escalation trial in healthy adult participants to evaluate the safety, tolerability, PK, PD, and immunogenicity of GB18.\n\nAs a humanized GDF15 monoclonal antibody, GB18 is expected to improve anorexia and weight loss caused by metabolic disorders driven by overactivation of the GDF15-GFRAL-RET signaling pathways. With favorable readouts of KXZY-GB18-101, this study aims to evaluate the effects of GB18 in patients with tumor cachexia. This open-label, multiple-ascending-dosing study will enroll 18-36 participants into 3 dosing-level cohorts (B1-B3, each with 6-12 participants).",[26],[55,56,57,58],"Cachexia","Cancer","GB18","First-in-patient","2026-06-10",{"date":61,"type":31},"2026-06-12",{"date":59,"type":31},{"date":64,"type":20},"2027-12-30",{"name":66,"class":38},"Kexing Biopharm Co., Ltd.",2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100633941","phase-2-intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia-100633941","NCT07533227","Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia","Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia: A Prospective, Multicenter, Single-arm, Phase II Clinical Study","FMT-CACH","Inclusion Criteria:\n\n1. Pre-advanced or advanced tumor cachexia stage.\n2. Age ≥ 18 years old, ECOG score 0-2, expected survival \\> 3 months.\n3. Patients with gastric cancer, colorectal cancer, or lung cancer who have received second-line or higher treatment.\n4. No FMT treatment in the past six months.\n\nExclusion Criteria:\n\n1. Any condition that affects gastrointestinal absorption, such as difficulty in swallowing, malabsorption, or uncontrollable vomiting; undergoing tube feeding or parenteral nutrition.\n2. Neurotic anorexia, anorexia caused by mental illness, or difficulty in eating due to pain.\n3. Acquired immunodeficiency syndrome.\n4. Currently taking or planning to take other drugs that increase appetite or weight, such as adrenal corticosteroids (except for short-term use of dexamethasone during chemotherapy), androgens, progestogens, salidroside, olanzapine, and anamorin or other appetite stimulants.\n5. Patients with Cushing's syndrome, adrenal or pituitary insufficiency; patients with difficult-to-control diabetes.\n6. Current imaging or clinical manifestations of gastrointestinal obstruction.\n7. Current uncontrolled coexisting diseases, including but not limited to decompensated cirrhosis, renal failure, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or mental illnesses\u002Fsocietal conditions that may limit patient compliance with study requirements or affect the patient's ability to provide written informed consent.\n8. Within 12 months prior to the first administration, there was unstable angina pectoris, myocardial infarction, congestive heart failure (grade 2 or above according to the New York Heart Association functional classification), or vascular diseases (such as aneurysms with a risk of rupture), or other cardiac damages that may affect the safety evaluation of the study drug (such as poorly controlled arrhythmias, myocardial ischemia); within 6 months prior to the first administration, there was esophageal-gastric varices, severe ulcers, gastrointestinal perforation and\u002For fistula history, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), intra-abdominal abscess or history of acute gastrointestinal bleeding.\n9. Within 4 weeks prior to the first administration, a serious infection occurred, including but not limited to conditions requiring hospitalization.",{"count":77,"type":20},66,[23],"This project is a prospective, multicenter, single-arm, phase II clinical study aimed at evaluating the efficacy and safety of fecal microbiota transplantation (FMT) in treating advanced tumor cachexia.",[26,81],"Fecal Microbiota Transplantation (FMT)",[83,84,85],"cachexia","FMT","Fecal Microbiota Transplantation","NOT_YET_RECRUITING","2026-04-14",{"date":89,"type":31},"2026-04-16",{"date":91,"type":20},"2026-05-01",{"date":93,"type":20},"2027-05-01",{"name":95,"class":96},"Hua Jiang","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100607188","postbiotics-ameliorate-cachexia-in-patients-with-non-small-cell-lung-cancer-100607188","NCT07185308","Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer","Postbiotics Ameliorate Cancer Cachexia in Patients With Non-small-cell Lung Cancer: a Multicentre, Double-blind, Randomised Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of gender.\n\n   \\-\n2. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) classified as stage III-IV according to the 9th TNM edition of IASLC, who are either currently receiving or have completed chemotherapy combined with immunotherapy.\n\n   \\-\n3. Cachexia was diagnosed according to the international consensus criteria: involuntary weight loss \\>5 % within 6 months preceding screening, or BMI \\\u003C20 kg\u002Fm² combined with \\>2 % involuntary weight loss within the same period.\n\n   \\-\n4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 and an estimated life expectancy of ≥ 4 months.\n\n   \\-\n5. Prior to the first dose of study treatment, adequate organ function must be documented (no blood products, granulocyte-colony-stimulating factors, or thrombopoietic agents within 14 days before randomisation): 1) Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL;2)Platelet count ≥ 100 × 10\\^9\u002FL; 3) Haemoglobin \\> 90 g\u002FL; 4) Serum creatinine \\\u003C 1.5 × upper limit of normal (ULN) or creatinine clearance (Cockcroft-Gault) \\> 50 mL\u002Fmin; 5) Total bilirubin \\\u003C 1.5 × ULN (\\\u003C 3 × ULN in Gilbert's syndrome) ;6) AST and ALT \\\u003C 2.5 × ULN (≤ 5 × ULN if hepatic metastases present); 7) INR and aPTT ≤ 1.5 × ULN unless the participant is on therapeutic anticoagulation; 8) Left-ventricular ejection fraction (LVEF) \\> 50 %\n\n   \\-\n6. Participants must be capable of providing written informed consent and comprehending the potential risks associated with the intervention.\n\n   \\-\n7. Participants must demonstrate high adherence to the study protocol.\n\n   \\-\n8. Gastrointestinal function score of \\\u003C 5.\n\nExclusion Criteria:\n\n1. Current presence of reversible causes of reduced food intake (e.g., oral mucositis or mechanical obstruction).\n\n   \\-\n2. Participants who are receiving tube feeding or parenteral nutrition at the time of screening or randomization.\n\n   \\-\n3. Cachexia attributable to other etiologies (e.g., chronic obstructive pulmonary disease, heart failure, or HIV\u002FAIDS).\n\n   \\-\n4. Major surgery within 4 weeks prior to randomization or major surgery planned during the study period.\n\n   \\-\n5. Initiation of systemic corticosteroid therapy within 4 weeks prior to randomization.\n\n   \\-\n6. Use of any appetite- or weight-enhancing agent within 30 days before randomisation, including anamorelin, megestrol acetate, cannabinoids, olanzapine, or mirtazapine.\n\n   \\-\n7. Use of antibiotics or probiotic-containing medications\u002Ffoods within 2 weeks prior to randomization.\n\n   \\-\n8. Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight reduction within 30 days prior to randomization.\n\n   \\-\n9. Pregnant or lactating women.\n\n   \\-\n10. Participants who are unable to understand the study objectives or who do not agree to comply with the study requirements.\n\n    \\-\n11. Individuals who lack full legal capacity or whose legal capacity is restricted.\n\n    \\-\n12. Any medical condition that could interfere with the interpretation of study results or increase the participant's risk in the opinion of the investigators.\n\n    \\-\n13. Participation in any other clinical trial.\n\n    \\-\n14. Gastrointestinal function score of ≥ 5.",{"count":105,"type":20},150,[107],"NA","This study aims to evaluate the efficacy of the oral postbiotic preparation JK-5G in improving body weight among patients with non-small-cell lung cancer (NSCLC)-related cachexia. By means of a randomized controlled trial, we will compare the between-group difference in body-weight changes between the JK-5G and placebo arms to clarify its nutritional therapeutic benefit.",[26],[111,112,113],"Non-small-cell lung cancer","Cachexixa","Postbiotics","2025-09-22",{"date":116,"type":31},"2025-09-25",{"date":118,"type":20},"2025-11-01",{"date":120,"type":20},"2026-12-31",{"name":122,"class":96},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":123},"100393716","routine-evaluation-of-people-living-with-cancer-100393716","NCT04406662","Routine Evaluation of People Living With Cancer","Routine Evaluation of People Living With Cancer - Body Composition, Physical Function, Systemic Inflammatory Response, Quality of Life and Symptoms","REVOLUTION","Inclusion Criteria:\n\n* Patients with incurable cancer (metastatic cancer (Clinical, histological, cytological or radiological evidence) or receiving anti-cancer therapy with palliative intent).\n* Aged 18-years and over\n* Written informed consent\n\nExclusion Criteria:\n\n* Any concomitant medical or psychiatric problems which, in the opinion of the investigator, would increase the risk of complication for the participant and\u002For investigator.\n* Participants will not be able to take part in bio-impedance analysis if they have a pacemaker or implantable cardiac defibrillator.",{"count":133,"type":20},600,"OBSERVATIONAL","People with incurable cancer often have complex individual needs, however there are several common themes encountered when considering this group.\n\nAs cancer progresses there are series of interactions between the tumour and the patient, producing both local and systemic effects. This altered state of illness can have multiple ill effects including weight loss, fatigue, increased symptom burden and reduction in physical function which all contribute to a reduced quality of life.\n\nThese areas are often studied in isolation, giving an incomplete picture. A detailed, holistic characterisation of this group of people does not exist.\n\nA robust characterisation of people with incurable cancer will allow identification and prioritisation of future research and has the potential to inform new therapeutics and provide justification for treatments.\n\nThis study aims to collect information about symptoms and quality of life, weight loss and body composition, physical activity and the body's immune response to cancer.\n\nParticipants with incurable cancer will be recruited to the study from oncology and palliative medicine services in the UK. Participants will answer questionnaires about quality of life and symptoms, have bloods taken for inflammatory marker and cytokine analysis and have their body composition measured by a variety of methods.",[26,137,138],"Advanced Cancer","Quality of Life",[140,141,142,143,144,145,83,146,147,148],"cancer","advanced cancer","incurable cancer","body composition","physical function","symptoms","quality of life","systemic inflammatory response","palliative medicine","2025-06-30",{"date":151,"type":31},"2025-07-03",{"date":153,"type":31},"2020-07-15",{"date":155,"type":20},"2029-08-08",{"name":157,"class":96},"University of Edinburgh"]